Legal & General Group Plc Buys Shares of 1,173,286 Illumina, Inc. $ILMN

Legal & General Group Plc bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,173,286 shares of the life sciences company’s stock, valued at approximately $206,299,000. Legal & General Group Plc owned approximately 0.78% of Illumina as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Illumina during the second quarter valued at about $3,374,423,000. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Illumina during the second quarter valued at approximately $293,846,000. Invesco Ltd. increased its stake in Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after acquiring an additional 1,352,731 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Down 0.1%

NASDAQ:ILMN opened at $224.84 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a market cap of $33.95 billion, a P/E ratio of 41.95, a P/E/G ratio of 3.17 and a beta of 1.45. The stock has a 50-day simple moving average of $191.66 and a 200-day simple moving average of $154.42. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $227.70.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. This represents a 2.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director directly owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. The trade was a 17.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,874,458 shares of company stock valued at $367,996,424 in the last ninety days. 2.90% of the stock is owned by company insiders.

Analyst Ratings Changes

ILMN has been the subject of several analyst reports. Barclays increased their price target on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. Stifel Nicolaus raised their target price on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. JPMorgan Chase & Co. upped their price objective on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Citigroup increased their price objective on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.